BioStem Technologies completed the acquisition of surgical and wound care bussines of BioTissue.

BioStem Technologies, a regenerative medicine company that develops, manufactures, and sells allografts derived from donated perinatal tissue, completed the acquisition of the surgical and wound care bussines of BioTissue, a biotechnology company focused on regenerative medicine. Financial terms were not disclosed. "Since our founding, our mission has been to transform patient outcomes through regenerative therapies. This divestiture is a catalyst for our next chapter, one focused squarely on eye care innovation. With a streamlined portfolio and dedicated resources, we are poised to deliver breakthrough solutions and support to our ocular customers and their patients. At the same time, BioStem's commitment to advancing surgical and wound care applications ensures our technology continues to make a profound impact on physicians and patients across specialties. We are grateful to the Surgical team for their contributions and are excited to see them thrive with BioStem," Ted Davis, BioTissue President and CEO.